DBV Technologies (NASDAQ:DBVT) Upgraded at Wall Street Zen

DBV Technologies (NASDAQ:DBVT) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday.

DBVT has been the topic of a number of other research reports. Guggenheim reiterated a “buy” rating and issued a $51.00 price target (up previously from $35.00) on shares of DBV Technologies in a research note on Wednesday, December 17th. HC Wainwright set a $40.00 target price on shares of DBV Technologies in a research note on Thursday, December 18th. Citizens Jmp increased their price target on shares of DBV Technologies from $21.00 to $45.00 and gave the company a “market outperform” rating in a report on Wednesday, December 17th. Cantor Fitzgerald set a $48.00 price objective on shares of DBV Technologies in a report on Wednesday, December 17th. Finally, Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research report on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, DBV Technologies presently has an average rating of “Moderate Buy” and an average target price of $35.38.

DBV Technologies Trading Down 0.9%

Shares of NASDAQ:DBVT opened at $21.26 on Friday. The stock has a fifty day simple moving average of $19.35 and a two-hundred day simple moving average of $14.42. DBV Technologies has a 12-month low of $3.82 and a 12-month high of $26.18. The stock has a market capitalization of $853.80 million, a price-to-earnings ratio of -4.11 and a beta of -0.98.

Insider Buying and Selling

In other DBV Technologies news, major shareholder Bpifrance Epic sold 1,292,103 shares of DBV Technologies stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $4.19, for a total value of $5,413,911.57. Following the completion of the sale, the insider owned 7,303,369 shares of the company’s stock, valued at approximately $30,601,116.11. The trade was a 15.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 3,369,627 shares of company stock valued at $15,489,908. Insiders own 1.44% of the company’s stock.

Institutional Trading of DBV Technologies

Several large investors have recently modified their holdings of DBVT. Vivo Capital LLC purchased a new stake in DBV Technologies during the second quarter valued at $9,659,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of DBV Technologies during the 2nd quarter valued at about $9,659,000. MPM Bioimpact LLC purchased a new stake in shares of DBV Technologies during the 2nd quarter valued at about $9,649,000. Octagon Capital Advisors LP bought a new position in shares of DBV Technologies in the 2nd quarter worth approximately $9,315,000. Finally, UBS Group AG lifted its stake in shares of DBV Technologies by 165,347.3% in the 4th quarter. UBS Group AG now owns 244,862 shares of the company’s stock worth $4,694,000 after purchasing an additional 244,714 shares during the period. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.